Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DRP8H0
|
|||
| Drug Name |
Evorpacept
|
|||
| Synonyms |
ALX148
Click to Show/Hide
|
|||
| Indication | Gastric cancer [ICD-11: 2B72] | Phase 2/3 | [1] | |
| Company |
ALX Oncology
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen CD47 (CD47) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05002127) A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). U.S.National Institutes of Health. | |||
| REF 2 | Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2021 Dec;22(12):1740-1751. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.